Psoriasis registries worldwide: systematic overview on registry publications
L Eissing, SJ Rustenbach, M Krensel… - Journal of the …, 2016 - Wiley Online Library
Background Safety and efficacy of new treatments are analyzed in clinical trials but their
capacity to show potential effects of long‐term treatment and more than short latency of …
capacity to show potential effects of long‐term treatment and more than short latency of …
Review of European registries for psoriasis
Background: Patient registries are databases that contain clinical data for patients with a
specific disease or medical condition. Objective: The purpose was to identify psoriasis …
specific disease or medical condition. Objective: The purpose was to identify psoriasis …
Use of topical antipsoriatic drugs in Denmark: a nationwide drug utilization study
MT Svendsen, MS Ernst, KE Andersen… - British Journal of …, 2019 - academic.oup.com
Background The reported real‐life use of prescribed topical antipsoriatic drugs is conflicting
and based on heterogeneous data sources. Objectives To describe the utilization of topical …
and based on heterogeneous data sources. Objectives To describe the utilization of topical …
Novel biological therapies in severe asthma: targeting the right trait
G Varricchi, G Marone, G Spadaro… - Current medicinal …, 2019 - ingentaconnect.com
Asthma is a heterogeneous disease characterized by chronic airway inflammation that
results in a wide spectrum of clinical manifestations. Patients with severe asthma represent a …
results in a wide spectrum of clinical manifestations. Patients with severe asthma represent a …
Evaluación de la eficiencia de los tratamientos biológicos en la psoriasis moderada a grave en España: análisis de coste por número necesario a tratar (NNT)
M Núñez, T Huete, P de la Cueva, JA Sacristán… - Actas Dermo …, 2019 - Elsevier
Antecedentes y objetivos La psoriasis es una enfermedad inflamatoria crónica de la piel
cuya prevalencia en España se estima en el 2, 3% de la población y en la que alrededor del …
cuya prevalencia en España se estima en el 2, 3% de la población y en la que alrededor del …
[PDF][PDF] A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price.
J Albrecht, S Gerdes - British Journal of Dermatology, 2016 - researchgate.net
Systemic drugs for psoriasis are limited, and vary between countries, 1 until they converge
on biologics. 2 In general, many dermatologists use ciclosporin for rapid control, followed by …
on biologics. 2 In general, many dermatologists use ciclosporin for rapid control, followed by …
Basal cell carcinoma screening drives a comprehensive approach to skin cancer.
OJ Wisco, D Adelson - British Journal of Dermatology, 2016 - search.ebscohost.com
REV_ISS_WEB_BJD_14611_174-6 1179..1193 Page 1 4 Horner MJ, Altekruse SF, Zou Z et al. US
geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality …
geographic distribution of prevaccine era cervical cancer screening, incidence, stage, and mortality …
Psoríase: O Papel dos Biossimilares no Tratamento da Psoríase
IQ Martins - 2016 - search.proquest.com
Introdução: A psoríase é uma doença cutânea crónica, com uma prevalência significativa
em Portugal e no Mundo. Carateriza-se pela presença de placas eritematodescamativas …
em Portugal e no Mundo. Carateriza-se pela presença de placas eritematodescamativas …